Dilhan Kuru
Istanbul University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Dilhan Kuru.
Biotechnology & Biotechnological Equipment | 2009
Yelda Tarkan-Argüden; M. Cem Ar; Sukriye Yilmaz; Seniz Ongoren; Dilhan Kuru; Umit Ure; Ayşe Çırakoğlu; Ahmet Emre Eskazan; Gülgün S. Güven; Güven Çetin; S. Purisa; Zafer Baslar; Ayhan Deviren; Yildiz Aydin; Seniha Hacihanefioglu; Burhan Ferhanoglu; Nukhet Tuzuner; Birsen Ülkü; Teoman Soysal
ABSTRACT Chronic myeloid leukaemia (CML) is a clonal haematological disease characterised by t(9;22)(q34;q11) which is called Philadelphia (Ph) chromosome. Highly improved haematological and cytogenetic results were obtained in chronic phase CML with the introduction of imatinib. Occurrence of additional cytogenetic abnormalities in Ph(+) cells is defined as clonal evolution (CE) and considered to be a preceding sign for acceleration. The most common additional chromosomal changes are +8, +Ph, i(17q), +19, -Y, +21, +17 and-7. The aims of this study were to delineate the occurrence pattern of cytogenetic clonal evolution in our cohort of CML patients and to investigate the impact on the course and prognosis of CML. Additional clonal chromosomal changes in Ph(+) cells were observed in 20 cases (19%). The abnormalities seen were monosomy 21 (%35), -17 (%30), -19 and +8 in (%25), -7, -8, -13, -15, -22, +Ph, and different marker chromosomes (%20), -Y, -12, -14, -16, -20 (%15), +Y, -10, -18 (%10), and -X, -3, -9, +20, der(7;17)(q10;q10), der3?, der12? (%5). The findings of-Y, -7, -8, +8, -14, -15, -17, -18, -21, +Ph, der(7;17)(q10;q10) and del(7)(q11) have been recorded in more than one samples in at least one case. The clinical data of the 20 cases with CE were compared to 7 cases with no or minor cytogenetic response without CE and no statistically significant differences found. Considering their high frequency and persistence in successive samples, we recommend to trace -21 and -17 with FISH in addition to classical cytogenetics in CML cases.
Turkish journal of haematology : official journal of Turkish Society of Haematology | 2011
Dilhan Kuru; Yelda Tarkan Argüden; Muhlis Cem Ar; Ayşe Çırakoğlu; Seniz Ongoren; Sukriye Yilmaz; Ahmet Emre Eskazan; Ayhan Deviren; Teoman Soysal; Seniha Hacihanefioglu; Birsen Ülkü
OBJECTIVE The Philadelphia (Ph) chromosome, consisting of the t(9;22)(q34;q11) translocation, is observed in ~90% of patients with chronic myeloid leukemia (CML). Variant Ph translocations are observed in 5%-10% of CML patients. In variant translocations 3 and possibly more chromosomes are involved. Herein we report 6 CML patients with variant Ph translocations. METHODS Bone marrow samples were examined using conventional cytogenetic meth ods. Fluorescence in situ hybridization (FISH) with whole-chromosome paints and BCR-ABL 1D probes were used to confirm and/or complement the findings, and identify rearrangements beyond the resolution of conventional cytogenetic methods. RESULTS Variant Ph translocations in the 6 patients were as follows: t(7;22)(p22;q11), t(9;22;15)(q34;q11;q22), t(15;22)(p11;q11), t(1;9;22;3)(q24;q34;q11;q21), t(12;22)(p13;q11), and t(4;8;9;22)(q11;q13;q34;q11). CONCLUSION Among the patients, 3 had simple and 3 had complex variant Ph translocations. Two of the presented cases had variant Ph chromosomes not previously described, 1 of which had a new complex Ph translocation involving chromosomes 1, 3, 9, 22, and t(1;9;22;3)(q24;q34;q11;q21) apart from a clone with a classical Ph, and the other case had variant Ph translocation with chromosomes 4, 8, 9, and 22, and t(4;8;9;22)(q11;q13;q34;q11) full complex translocation. Number of studies reported that some patients with variant Ph translocation were poor responders to imatinib. All of our patients with variant Ph translocations had suboptimal responses to imatinib, denoting a poor prognosis also. Variant Ph translocations may be important as they are associated with prognosis and therapy for CML patients.
Turkish Journal of Hematology | 2015
Yelda Tarkan Argüden; Dilhan Kuru; Ayşe Çırakoğlu; Şükriye Yilmaz; Şeniz Öngören Aydın; Cem Ar; Ayhan Deviren; Teoman Soysal; Seniha Hacihanefioglu
Although chronic myeloid leukemia (CML) is characterized by the Philadelphia (Ph) chromosome, which is the result of t(9;22) (q34;q11) or its variants, 10%-20% of cases have additional cytogenetic abnormalities. The most common additional abnormalities are loss of the Y chromosome, +8, +Ph, and i(17q). Since these additional chromosome abnormalities are signs of disease progression, it is important to perform cytogenetic analyses periodically in patients with CML [1].
Human Reproduction | 1992
Tulay Irez; Hülya Senol; Meryem Alagöz; Cavidan Basmaciogullari; Feyhan Turan; Dilhan Kuru; Erdogan Ertungealp
Turkiye Klinikleri Tip Bilimleri Dergisi | 2009
Şeniz Öngören; Yelda Tarkan-Argüden; M. Cem Ar; Şükriye Yilmaz; Umit Ure; Dilhan Kuru; Ahmet Emre Eşkazan; Gülgün S. Güven; Güven Çetin; Ayşe Çirakoğlu; Zafer Başlar; Ayhan Deviren; Yildiz Aydin; Seniha Hacihanefioğlu; Burhan Ferhanoğlu; Nukhet Tuzuner; Birsen Ülkü; Teoman Soysal
Turkiye Klinikleri Tip Bilimleri Dergisi | 2010
Ayşe Çirakoğlu; Şükriye Yilmaz; Dilhan Kuru; Yelda Tarkan-Argüden; Gülgün S. Güven; Ayhan Deviren; Seyfettin Uludağ; Seniha Hacihanefioğlu
Turkish Thoracic Journal | 2016
Sezen Atasoy; Salih Serdar Erturan; Nail Yilmaz; Dilhan Kuru; Ayşe Çırakoğlu; Sukriye Yilmaz; Ayhan Deviren
Archive | 2015
Seda Eren; Dilhan Kuru
Journal of Clinical and Experimental Investigations | 2015
Seda Eren; Ayşe Çırakoğlu; Dilhan Kuru; Zafer Baslar; Omer Devecioglu; Meliha Nalcaci; Seniha Hacihanefioglu
Archive | 2014
Yelda Tarkan Argüden; Dilhan Kuru; Cem Ar; Ayhan Deviren; Teoman Soysal